Fig. 2

Waterfall plots for greatest change in target lesion size from baseline for the (a) selumetinib plus docetaxel and (b) selumetinib plus dacarbazine arms. Lower reference line indicates the point below which best response is partial response (>30% reduction). Upper reference line indicates the point above which best response is progressive disease (>20%). Administration of primary prophylactic granulocyte colony stimulating factor (ppG-CSF) differed between the part A selumetinib 75 mg bid cohort due to differences in treatment practices between study centers: ^aReceived primary ppG-CSF in cycle 1; ^bDid not receive ppG-CSF in cycle 1. Response Evaluation Criteria In Solid Tumors best response: N, not evaluable; P, progressive disease; R, partial response; S, stable disease. Population: Measurable disease at baseline and underwent follow-up scan